Results 11 to 20 of about 35,844 (248)

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study [PDF]

International Journal of Nephrology, 2017
Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients.
Hiroya Takami, Kazunori Washio, Hiromichi Gotoh   +2 more
doaj   +2 more sources

Effects of bisphosphonates after denosumab discontinuation and treatment effect heterogeneity using causal machine learning. [PDF]

Sci Rep
Kim M, Jeon N, Suh HS.
europepmc   +3 more sources

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review

ESMO Open, 2020
Objectives Giant cell tumour of bone (GCTB) is a rare tumour, generally managed with surgery. Treatment of the very rare unresectable advanced/metastatic GCTB is challenging and denosumab is the only current available medical option, an anti-RANKL ...
Alessandra Raimondi, Silvia Stacchiotti, Paolo G Casali, Noemi Simeone, Marco Guzzo, Massimo Maniezzo, Paola Collini, Carlo Morosi, Francesca Gabriella Greco, Anna Maria Frezza   +9 more
doaj   +1 more source

Does denosumab exert a protective effect against COVID-19? Results of a large cohort study

Frontiers in Endocrinology, 2023
IntroductionDenosumab is a monoclonal antibody blocking the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand (RANK/RANKL) pathway, thus inhibiting osteoclastogenesis.
Sara Cassibba, Silvia Ippolito, Silvia Pellegrini, Silvia Pellegrini, Roberto Trevisan, Roberto Trevisan, Alessandro Rossini   +6 more
doaj   +1 more source

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Journal of Bone Oncology, 2022
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck   +8 more
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Frontiers in Oncology, 2020
Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of ...
Hengyuan Li, Hengyuan Li, Junjie Gao, Junjie Gao, Youshui Gao, Nong Lin, Minghao Zheng, Zhaoming Ye   +7 more
doaj   +1 more source

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study

Bone Reports, 2021
Purpose: Denosumab reduces bone resorption and improves bone mineral density (BMD). Studies have analyzed subsequent treatment transitioning from bisphosphonates to denosumab based on dual-energy X-ray absorptiometry scanning (DXA). Quantitative computed
Koki Tsuchiya, Koji Ishikawa, Yoshifumi Kudo, Soji Tani, Takashi Nagai, Tomoaki Toyone, Katsunori Inagaki   +6 more
doaj   +1 more source

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases. [PDF]

, 2019
Denosumab has been used successfully to treat disease-associated osteoclast overactivity, including giant cell tumor of bone. Given its mechanism of action, denosumab is a potent potential treatment of other osteoclast bone dysplasias including central ...
Bernthal, Nicholas M, Bukata, Susan, Eilber, Fritz C, Federman, Noah C, Felsenfeld, Alan L, Nelson, Scott D, Singh, Arun, Upfill-Brown, Alexander, Wesseling-Perry, Katherine   +8 more
core   +2 more sources